MDxHealth Q2 Revenue Up 16% to $27.2M; $20M Direct Placement at $0.454
MDXH sits 39% above its 52-week low of $0.4.
Summary
MDxHealth reported Q2 revenue growth of 16% to $27.2M, but net loss widened to $9.5M. The company also disclosed a $20M registered direct placement at $0.454/share, adding 44.05M shares.
Key Events · Earnings and Guidance · MDXH
-
Q2 Revenue Up 16%
Revenue of $27.2M, up 16% YoY, with sequential growth of $3.3M from Q1. Tissue-based test volume increased 13% sequentially.
-
Net Loss Widens 36%
Net loss of $9.5M vs $7.0M prior year, driven by higher operating expenses from the ExoDx acquisition. Adjusted EBITDA was $(2.3)M vs $1.1M prior year.
-
$20M Registered Direct Placement
44,052,862 shares sold at $0.454/share on August 11, 2026, for gross proceeds of $20M. Pro-forma cash as of June 30, 2026 would be $39.2M.
-
Resolve Business Discontinued
Resolve mdx wind-down completed; Delta Lab executed an Assignment for the Benefit of Creditors on August 3, 2026, including a $10.4M Novitas recoupment claim.
Analysis · MDXH · Industrial Applications And Services
MDxHealth reported Q2 revenue of $27.2 million, up 16% year-over-year, but net loss widened 36% to $9.5 million. The company also disclosed a $20 million registered direct placement priced at $0.454 per share, executed August 11, 2026. The placement is highly dilutive — 44.05 million new shares represent a substantial increase to the share count — and comes as the company faces Nasdaq delisting notices for failing the $1.00 bid price and $35 million market value requirements. The capital raise provides runway but underscores the company's distressed position.
At the time of this filing, MDXH was trading at $0.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $23.7M. The 52-week trading range was $0.40 to $5.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.